Overview

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Status:
Terminated
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Incyte Biosciences International Sàrl
Treatments:
Pembrolizumab